Immunohistochemistry (IHC) Market Size, Share, Forecast, & Trends Analysis by Offering (Reagents [Fixation, Buffer, Blocking, Antibodies], Kits, Equipment [Staining, Imaging] Method (ABC, CSA, PAP) Process, Application, End User - Global Forecast to 2031

Immunohistochemistry Market Size & Forecast

The Immunohistochemistry Market is anticipated to reach $4.08 billion by 2031 at a CAGR of 7.2% from 2024–2031. A multitude of factors drives the growth of the immunohistochemistry market. These include the increasing prevalence of chronic diseases, particularly among the growing geriatric population, the heightened focus on rare diseases, the growing awareness of the importance of early disease diagnosis, the rising expenditure on research & development, the surging demand for drug discovery & development, the rising incidence of infectious diseases, the mounting funding for research activities, and the increasing healthcare expenditure.

Furthermore, proteomics inclination toward personalized medicine, advancements in genomics and proteomics, and increasing automation in immunohistochemistry are expected to offer significant growth opportunities for market growth.

Immunohistochemistry Market Growth Drivers

Rising Prevalence of Chronic Diseases Coupled with the Increasing Geriatric Population

The prevalence of chronic diseases and conditions such as cancer, diabetes, arthritis, and heart disease are on the rise globally. Cancer is one of the leading causes of death around the world. For instance, the World Health Organisation (WHO) 2022 report states that about 10 million deaths worldwide in 2020 were attributable to cancer, with 1.80 million of those deaths being caused by lung cancer. An increasing number of people are afflicted with chronic diseases, largely due to societal behaviors, including alcohol and tobacco use, physical inactivity, and bad diets, as well as the aging population. The International Diabetes Federation estimates that 6.7 million deaths worldwide in 2021 will be attributed to diabetes. The need for sophisticated laboratory IHC solutions to aid in the more accurate diagnosis of cancer and other diseases is growing due to the rise in chronic diseases and the aging population, which is less resistant to these conditions.

Click here to: Get Free Sample Pages of this Report

Increasing Research & Development Expenditure

Pharmaceutical companies are continually focusing on R&D, which is a critical component of medication development procedures. The biotechnology industry also makes significant investments in research & development to meet the growing need for innovation and new medical advances. The increasing number of medicine approvals demonstrates the importance of research and development. For example, according to a report published by the European Commission, the European Union would spend USD 374.1 billion on research and development in 2022, up 7% from 2021 and 47.5% from 2012. Furthermore, nations such as India and China are substantially investing in research and development, which is expected to increase demand for advanced research solutions, which in turn is expected to boost the demand for immunohistochemistry products.

Immunohistochemistry Market Trends

AI-Based Histochemistry

AI offers efficient workflow, serves as an additional tool for analysis, and standardizes reports for immunohistochemistry. AI immunohistochemistry is used for tumor diagnosis, which is made easy by the integration of AI. Various companies are providing AI-based software for immunohistochemistry analysis. For Instance, in December 2023, Indica Labs, Inc. (U.S) launched Breast IHC AI, an AI-powered decision support tool. This tool helps in the evaluation and quantification of breast cancer biomarkers, including ER, PR, HER2, and Ki67. Additionally, In March 2023, Visiopharm A/S (Denmark) launched Ki67 algorithm for Immunohistochemistry biomarker analysis. This algorithm provides strong identification of tumor cells, quantification, cell classification, and visualization. Thus, AI in histochemistry is expected to support the growth of the market.

Immunohistochemistry Market Opportunities

Increasing Inclination Towards Personalized Medicine 

Personalized medicine utilizes an individual's genomic information to provide personalized therapy. Precision medications not only help to cure diseases, but they also increase the chances of people surviving treatments for life-threatening conditions such as cancer. Cancer is among the main causes of death around the globe. For example, according to a report published by the World Health Organisation in 2022, nearly 10 million people perished from cancer worldwide. Immunohistochemistry aids in the diagnosis of cancer by predicting therapy responses and determining disease consequences (prognoses). As a result, the rising prevalence of cancer is driving up the use of personalized treatment, creating the potential for the immunohistochemistry market to grow.

Advancements in Genomics and Proteomics

Immunohistochemistry (IHC) provides a cost-effective technique for determining the molecular morphology of tissue and cell micro-architecture. IHC uses the Antigen-Antibody interaction for analyzing visualizing, quantifying, and phenotyping cells at a tissue level. Protein profiling done by the use of immunohistochemistry allows the visualization of the distribution of relative proteins in cancer genes present in tumor cells. Some proteins express differently for different forms of cancer. The availability of necessary and specific protein markers aids with accurate tumor diagnosis and classification. Also in genomics, IHC plays an important role in diagnostics, with many biomarkers that the technique can currently detect. Thus, the advancements in genomics and proteomics and the use of IHC in these fields are expected to increase the demand for IHC solutions, which is expected to drive the growth of the market.

Immunohistochemistry Market Analysis: Key Findings

By Offering: In 2024, the Consumables Segment to Dominate the Immunohistochemistry Market

Based on offering, the immunohistochemistry market is segmented into consumables, equipment, and services & software. In 2024, the consumables segment is expected to account for a large share of 68.4% of the immunohistochemistry market. The consumables segment is further sub-segmented into reagents, kits, and other accessories. Advancements in kits and reagents enable laboratories to perform multiple tests simultaneously. Other factors, such as the rising prevalence of chronic diseases and increased genetic and rare disease research by biopharmaceutical companies, contract research organizations, and research laboratories, drive the demand for IHC kits and reagents.

By Method: In 2024, the Avidin-Biotin Complex Segment to Dominate the Immunohistochemistry Market

Based on method, the immunohistochemistry market is segmented into avidin-biotin complex, polymer-based immunohistochemistry, catalyzed signal amplification (CSA), fluorescyl-tyramide amplification, improved catalyzed signal amplification (ICSA), multi-staining immunohistochemistry, labeled streptavidin-biotin (LSAB), and pap method. In 2024, the avidin-biotin complex segment is expected to account for the largest share of 30.8% of the immunohistochemistry market. The large market share of this segment is attributed to the various advantages offered by avidin-biotin complex, which include resistivity to enzymatic reactions, PH changes, temperature, denaturation, and organic reagents, increased detection efficiency, requiring less primary antibody, and less assay time as compared to other methods.

By Application: In 2024, the Clinical Applications Segment to Dominate the Immunohistochemistry Market

Based on application, the immunohistochemistry market is segmented into research applications and clinical applications. In 2024, the clinical applications segment is expected to account for the largest share of the immunohistochemistry market. The clinical applications segment is further sub-segmented into reproductive health, oncology, infectious disease, and other clinical applications. Factors driving the growth of this segment include the increasing incidence of cancer, the rising awareness among healthcare professionals about the advantages of immunohistochemistry testing for treatment purposes, and the increasing number of diagnostic laboratories. For instance, cancer is one of the leading causes of death across the globe. According to WHO, approximately 400,000 children develop cancer per year in the world, increasing the demand for immunohistochemistry tests for the detection of the disease.

By End User: In 2024, the Hospitals & Diagnostic Laboratories Segment to Dominate the Immunohistochemistry Market

Based on end user, the immunohistochemistry market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic institutes & research centers, and other end users. In 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the immunohistochemistry market. This segment’s large market share is attributed to the increasing prevalence of cancer, rising healthcare expenditure, and the growing number of hospitals in both developed and developing countries. Furthermore, more inclination of patients toward hospitals due to developed infrastructure, availability of skilled professionals, and availability of advanced treatments.

Geographical Analysis

In 2024, North America is expected to account for the largest share of 38.4% of the immunohistochemistry market. North America's significant market share is attributed to the presence of key immunohistochemistry technology and product providers, high prevalence of chronic and infectious diseases, high awareness regarding early disease diagnosis, growing adoption of advanced diagnostic products, and rising funding activities coupled with novel developments in clinical and research technologies.

Moreover, Asia-Pacific is poised to register the highest CAGR of 13% during the forecast period. This region’s growth is attributed to continuous improvements in healthcare infrastructure, the rising number of hospitals, and increasing government investments in this sector. Accelerated economic growth in many countries of the Asia-Pacific region has relatively increased the focus of various governments on the healthcare sector in terms of increased investments to enhance the accessibility to healthcare facilities and build better healthcare infrastructure. For instance, according to a report published by the Ministry of Finance of India, for the year 2022-2023 Central and State Governments' budget for healthcare is 2.1% of total gross domestic product (GDP).

Immunohistochemistry Market: Key Companies

The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years (2021–2024). The key players operating in the global immunohistochemistry market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories Inc. (U.S.), Eagle Biosciences, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S), Cell Signaling Technology, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio SB Inc. (U.S.), Biocare Medical, LLC. (U.S.), Bio-Genex Laboratories (U.S.), and CANDOR Bioscience GmbH (Germany).

Immunohistochemistry Industry Overview: Latest Developments from Key Industry Players

• In February 2023, F. Hoffmann-La Roche Ltd (Switzerland) collaborated with Janssen, a division of Johnson & Johnson Pte. Ltd. (U.S.) for precision medicine with various companion diagnostic technologies, which includes digital pathology, immunohistochemistry, next-generation sequencing, immunoassays, and polymerase chain reaction (PCR).
• In January 2023, Agilent Technologies, Inc. (U.S.) partnered with Akoya Biosciences, Inc. (U.S) to develop multiplex-immunohistochemistry diagnostic solutions for the analysis of tissue and for commercializing workflow solutions.
• In October 2022, F. Hoffmann-La Roche Ltd (Switzerland) launched Anti-PRAME (EPR 20330), a Rabbit Monoclonal Primary Antibody. This antibody is used to identify protein expression in tissue samples.

Immunohistochemistry Market Research Summary

Key questions answered in the immunohistochemistry market report: